Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S834-S837

  Singh, Dolly ^a   Dhummakupt, Adit ^a   Siems, Lilly ^a   Persaud, Deborah ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral drug resistance.; Dried blood spot; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; CHEMOPROPHYLAXIS; DRIED BLOOD SPOT TESTING; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROCEDURES; VIROLOGY;

ANTI-HIV AGENTS; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; POPULATION SURVEILLANCE;

EID: 85038129776     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix386     Document Type: Article

References (35)

1. UNAIDS. Global AIDS update. Geneva: World Health Organization, 2016.
2. UNAIDS. Global HIV statistics fact sheet, November 2016. Geneva: UNAIDS, 2016.
3. World Health Organization (WHO). WHO HIV drug resistance report 2012. Geneva: WHO, 2012.
4. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8.
5. Boerma RS, Sigaloff KC, Akanmu AS, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-Analysis. J Antimicrob Chemother 2017; 72:365-71.
6. Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis 2012; 54(Suppl 4):S245-9.
7. Sebire K, McGavin K, Land S, Middleton T, Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCRbased assay. J Clin Microbiol 1998; 36:493-8.
8. Amellal B, Murphy R, Maiga A, et al. Stability of HIV RNA in plasma specimens stored at different temperatures. HIV Med 2008; 9:790-3.
9. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol 1998; 36:1471-9.
10. Parry CM, Parkin N, Diallo K, et al. Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. J Clin Microbiol 2014; 52:2868-75.
11. Salimo AT, Ledwaba J, Coovadia A, et al. The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods 2015; 223:30-2.
12. World Health Organization (WHO). WHO manual for HIV drug resistance testing using dried blood spot specimens. Geneva: WHO, 2012.
13. World Health Organization (WHO). Technical and operational considerations for implementing HIV viral load testing: interim technical update. Geneva: WHO, 2014.
14. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-13.
15. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008; 41:283-7.
16. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-11.
17. Johannessen A, Garrido C, Zahonero N, Naman E, de Mendoza C. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. J Antimicrob Chemother 2011; 66:260-4.
18. Monleau M, Aghokeng AF, Eymard-Duvernay S, et al.; ANRS 12235 Study Group. Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol 2014; 52:578-86.
19. Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 2012; 54:1187-95.
20. Dickover RE, Herman SA, Saddiq K, Wafer D, Dillon M, Bryson YJ. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J Clin Microbiol 1998; 36:1070-3.
21. Prosperi MC, Mackie N, Di Giambenedetto S, et al.; SEHERE Consortium. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011; 66:1886-96.
22. Santoro MM, Fabeni L, Armenia D, et al. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis 2014; 58:1156-64.
23. Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 2014; 58:1165-73.
24. Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One 2015; 10:e0117430.
25. Wirden M, Soulie C, Valantin MA, et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother 2011; 66:709-12.
26. Reigadas S, Schrive MH, Aurillac-Lavignolle V, Fleury HJ. Quantitation of HIV-1 RNA in dried blood and plasma spots. J Virol Methods 2009; 161:177-80.
27. Rodriguez-Auad JP, Rojas-Montes O, Maldonado-Rodriguez A, et al. Use of dried plasma spots for HIV-1 viral load determination and drug resistance genotyping in mexican patients. Biomed Res Int 2015; 2015:240407.
28. Plantier JC, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS 2005; 19:391-7.
29. Sawadogo S, Shiningavamwe A, Chang J, et al. Limited utility of dried-bloodand plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0. J Clin Microbiol 2014; 52:3878-83.
30. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother 2010; 65:1562-6.
31. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 2010; 12:195-208.
32. Ziemniak C, Mengistu Y, Ruff A, et al. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol 2011; 49:4077-82.
33. Salazar-Gonzalez JF, Salazar MG, Tully DC, et al. Use of dried blood spots to elucidate full-length transmitted/founder HIV-1 genomes. Pathog Immun 2016; 1:129-53.
34. Ji H, Li Y, Liang B, et al. Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naive and experienced patients. PLoS One 2013; 8:e56170.
35. Templer SP, Seiverth B, Baum P, Stevens W, Seguin-Devaux C, Carmona S. Improved sensitivity of a dual-target HIV-1 qualitative test for plasma and dried blood spots. J Clin Microbiol 2016; 54:1877-82.